spectrochip g384 (agena bioscience)
agena bioscience is a verified supplier 
agena bioscience manufactures this product 
90
Structured Review
agena bioscience
spectrochip g384
Spectrochip G384, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spectrochip+g384/spectrochip+g384/pmc11986751-231-6-21
Average 90 stars, based on 1 article reviews
Spectrochip G384, supplied by agena bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spectrochip+g384/spectrochip+g384/pmc11986751-231-6-21
Average 90 stars, based on 1 article reviews
spectrochip g384 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: The Association Between PNPLA2 Methylation in Peripheral Blood and Early-Stage Lung Cancer in a Case–Control Study Article Snippet: The final products were transferred to a SpectroCHIP G384 and detected by the Mass Spectrometry:Article Title: Construction and analysis of the invasive prediction model for pulmonary nodules: based on clinical, CT image and DNA methylation characteristics Article Snippet: The PCR products were incubated with shrimp alkaline phosphatase (SAP), processed by T-cut assay (Agena Bioscience, San Diego, California, USA), and further purified by resin. .. The final product was transferred to SpectroCHIP G384 and detected by Article Title: FYB Methylation in Peripheral Blood as A Potential Marker for the Early-stage Lung Cancer: A Case-control Study in Chinese Population Article Snippet: Background: Lung cancer (LC) is the leading cause of cancer-related morbidity and mortality in China.. Exploring novel biomarkers for the early detection of LC is important.. Materials and methods: We quantified DNA methylation levels of three CpG sites of FYB gene in peripheral blood in 163 early-stage LC cases (88.3% at stage I) and 187 ageand gender-matched healthy controls. |
